← Back to Patent Explorer
US3873715A Expired / Lapsed US ⏱️ 0.0 years remaining

Therapeutic agent for improving cardiovascular function

Assignee: University of Miami
•
Filing: 1973-04-06
•
Granted: 1975-03-25
•
Expires: 1993-04-06
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Methods of and compositions for a therapeutic agent for improving cardiovascular function utilizing as the active agent a compound represented by the formula WHEREIN R1 is hydrogen or acetyl; R2 is hydrogen, bromine or chlorine, AND THE PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, ARE DISCLOSED.

Inventors

  • 👤 Berton Charles Pressman
  • 👤 Guzman Norberto Tumali De

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-02 11:26
CPC Classifications
C; C07; C07D; C07D407/00; C07D407/02; C07D407/04

Claims Analysis

Total Claims: 12
Claim 1
Independent Claim 28 words
A METHOD FOR IMPROVING CARDIOVASCULAR FUNCTION IN A PATIENT REQUIRING SUCH TREATMENT WHICH COMPRISES ADMINISTERING TO SUCH PATIENT AN EFFECTIVE AMOUNT OF A COMPOUND REPRESENTED BY THE FORMULA
Claim 2
Independent Claim 28 words
A METHOD FOR IMPROVING CARDIOVASCULAR FUNCTION IN A PATIENT REQUIRING SUCH TREATMENT WHICH COMPRISES ADMINISTERING TO SUCH PATIENT AN EFFECTIVE AMOUNT OF A COMPOUND REPRESENTED BY THE FORMULA
Claim 3
Dependent Claim 13 words
The method of claim 1 wherein the compound is 3-methyl-6(7-ethyl-4-hydroxy-3,5-dimethyl-6-oxo-7-(5-ethyl-3-methyl-5-(5 -ethyl-5-hydroxy-6-methyl-2-tetrahydropyranyl)-2 -tetrahydrofuryl)heptyl)salicylic acid.
Claim 4
Dependent Claim 12 words
The method of claim 1 wherein the compound is 5-bromo-3-methyl-6-(7-ethyl-4-hydroxy-3,5-dimethyl-6-oxo-7-(5-ethyl-3-methyl-5-(5-ethyl-5-hydroxy-6-methyl-2-tetrahydropyranyl)-2 -tetrahydrofuryl)heptyl)salicylic acid.
Claim 5
Dependent Claim 14 words
The method of claim 1 wherein the compound is 3-methyl-6-(7-ethyl-4-hydroxy-3,5-dimethyl-6-oxo-7-(5-ethyl-3-methyl-5-(5 -ethyl-5-hydroxy-6-methyl-2-tetrahydropyranyl)-2 -tetrahydrofuryl)heptyl)acetyl salicylic acid.
Claim 6
Dependent Claim 14 words
The method of claim 1 wherein the compound is 5-chloro-3-methyl-6-(7-ethyl-4-hydroxy-3,5-dimethyl-6-oxo-7-(5-ethyl-3 -methyl-5-(5-ethyl-5-hydroxy-6-methyl-2-tetrahydropyranyl)-2 -tetrahydrofuryl)heptyl) salicylic acid.
Claim 7
Dependent Claim 34 words
A parenteral composition for producing myocardial stimulation in patients requiring such effects comprising an inert non-toxic pharmaceutically acceptable parenteral vehicle and an effective amount of an active compound in solution represented by the formula
Claim 8
Dependent Claim 34 words
A parenteral composition for producing myocardial stimulation in patients requiring such effects comprising an inert non-toxic pharmaceutically acceptable parenteral vehicle and an effective amount of an active compound in solution represented by the formula
Claim 9
Dependent Claim 14 words
The composition of claim 6 wherein the active compound is 3-methyl-6-(7-ethyl-4-hydroxy-3,5-dimethyl-6-oxo-7-(5-ethyl-3-methyl-5-(5 -ethyl-5-hydroxy-6-methyl-2-tetrahydropyranyl)-2 -tetrahydrofuryl)heptyl)salicylic acid.
Claim 10
Dependent Claim 14 words
The composition of claim 6 wherein the active compound is 5-bromo-3-methyl-6-(7-ethyl-4-hydroxy-3,5-dimethyl-6-oxo-7-(5-ethyl-3-methyl-5-(5-ethyl-5-hydroxy-6-methyl-2-tetrahydropyranyl)-2 -tetrahydrofuryl)heptyl) salicylic acid.
Claim 11
Dependent Claim 15 words
The composition of claim 6 wherein the active compound is 3-methyl-6-(7-ethyl-4-hydroxy-3,5-dimethyl-6-oxo-7-(5-ethyl-3-methyl-5-(5 -ethyl-5-hydroxy-6-methyl-2-tetrahydropyranyl)-2 -tetrahydrofuryl)heptyl)acetyl salicylic acid.
Claim 12
Dependent Claim 15 words
The composition of claim 6 wherein the active compound is 5-chloro-3-methyl-6-(7-ethyl-4-hydroxy-3,5-dimethyl-6-oxo-7-(5-ethyl-3 -methyl-5-(5-ethyl-5-hydroxy-6-methyl-2-tetrahydropyranyl)-2 -tetrahydrofuryl)heptyl) salicylic acid.

References Cited (Backward Citations)

US3715372A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1978-03-24 1978-09-23 1979-03-25 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1982-03-24 1982-09-23 1983-03-25 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1986-03-24 1986-09-23 1987-03-25 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag